Furthermore, the deceased patients had relatively reduced expression of FTO, METTL3, and METTL14 in tumor tissues, and increased levels of YTHDF1 and YTHDF3 than the alive patients who were diagnosed with breast cancer at the same period (Figure 2F). This evidence concerns the gene FTO and neoplasm.